Historie von Umsatz, Gewinn und Cashflow aus den offiziellen Geschäftsberichten.
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung.
Interaktive Charts und vollständige Abschlüsse ansehen → Bewertungsmodell (DCF) →
| Gewinn- und Verlustrechnung | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gesamtumsatz | $11.0B | $10.1B | $8.4B | $7.1B | $6.2B | $5.7B | $4.4B | $4.5B | $3.7B | $3.1B | $2.7B | $2.4B | $2.1B | $2.3B | $2.2B | $1.8B | $1.4B | $1.1B | $875M | $601M | $373M |
| Bruttoergebnis | $7.4B | $6.6B | $5.6B | $4.7B | $4.2B | $4.0B | $2.9B | $3.1B | $2.6B | $2.2B | $1.9B | $1.6B | $1.4B | $1.6B | $1.6B | $1.3B | $1.0B | $751M | $621M | $414M | $248M |
| Bruttomarge % | 66.7% | 66.0% | 67.5% | 66.4% | 67.4% | 69.3% | 65.6% | 69.5% | 69.9% | 70.1% | 69.9% | 66.2% | 66.3% | 70.4% | 72.1% | 72.5% | 72.9% | 71.4% | 71.0% | 69.0% | 66.5% |
| Betriebsergebnis (EBIT) | $3.5B | $2.9B | $2.3B | $1.8B | $1.6B | $1.8B | $1.1B | $1.4B | $1.2B | $1.1B | $945M | $740M | $545M | $852M | $878M | $695M | $555M | $377M | $311M | $207M | $107M |
| Operative Marge % | 31.3% | 29.3% | 28.1% | 24.8% | 25.4% | 31.9% | 24.1% | 30.7% | 32.2% | 33.7% | 34.9% | 31.0% | 25.6% | 37.6% | 40.3% | 39.5% | 39.3% | 35.9% | 35.5% | 34.4% | 28.8% |
| Jahresüberschuss | $3.1B | $2.9B | $2.3B | $1.8B | $1.3B | $1.7B | $1.1B | $1.4B | $1.1B | $660M | $736M | $589M | $419M | $671M | $657M | $495M | $382M | $233M | $204M | $145M | $72M |
| Nettomarge % | 28.4% | 28.4% | 27.8% | 25.2% | 21.2% | 29.8% | 24.3% | 30.8% | 30.3% | 21.1% | 27.2% | 24.7% | 19.7% | 29.6% | 30.1% | 28.2% | 27.0% | 22.1% | 23.4% | 24.1% | 19.3% |
| EBITDA | $4.5B | $4.0B | $3.1B | $2.4B | $2.0B | $2.1B | $1.3B | $1.6B | $1.3B | $1.2B | $1.0B | $830M | $619M | $920M | $936M | $741M | $596M | $412M | $336M | $220M | $143M |
| Ergebnis je Aktie (EPS) | $8.72 | $7.87 | $6.42 | $5.03 | $3.65 | $4.66 | $2.94 | $3.85 | $3.16 | $1.89 | $2.08 | $1.73 | $1.23 | $1.86 | $1.78 | $1.37 | $1.05 | $0.66 | $0.57 | $0.41 | $0.21 |
| Ausstehende Aktien (Mio.) | 358M | 363M | 362M | 357M | 362M | 366M | 361M | 359M | 356M | 349M | 354M | 341M | 339M | 361M | 370M | 362M | 363M | 353M | 359M | 351M | 343M |
Quelle: veröffentlichte Unternehmensberichte (SEC). Bitte prüfen Sie die Zahlen vor Verwendung auf SEC EDGAR.
Bilanzen, Cashflow-Rechnungen, Quartalsdaten und alle Kennzahlen finden Sie im interaktiven Viewer für ISRG. /companies/us/ISRG
Die Informationen auf dieser Website dienen ausschließlich Bildungs- und Informationszwecken und stellen keine Anlageberatung dar. Es werden keine Kursziele und keine Anlageurteile veröffentlicht.
About TickerBase · Data methodology & sources · Privacy · Terms